N. Nupponen

发表

Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

A. Schäffer, O. Kallioniemi, J. Isola, 1997, Cancer research.

Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.

P S Meltzer, M. Ringnér, Y. Chen, 2001, Cancer research.

Genetic alterations in hormone-refractory recurrent prostate carcinomas.

T. Visakorpi, P. Koivisto, L. Kakkola, 1998, The American journal of pathology.

Germline mutations in the ribonuclease L gene in families showing linkage with HPC1

K. Klinger, P. Meltzer, J. Carpten, 2002, Nature Genetics.

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines

Alexander Schepsky, Thorkell Gudjonsson, A. Slipicevic, 2020, Cancer medicine.

Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme

H. Joensuu, H. Sihto, O. Tynninen, 2005, The Journal of pathology.

Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ‐line mutation carriers

Å. Borg, J. Isola, M. Tanner, 2000, Genes, chromosomes & cancer.

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

B. Neyns, A. Michotte, O. Tynninen, 2011, Journal of Neuro-Oncology.

Molecular pathology of gliomas

H. Joensuu, N. Nupponen, 2006 .

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen

A. Slipicevic, C. Heckman, A. Eskelinen, 2022, Cells.

Molecular genetic analysis of the REST/NRSF gene in nervous system tumors

A. Paetau, M. Tanner, H. Haapasalo, 2006, Acta Neuropathologica.

A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy

M. Ruutu, A. Hemminki, T. Joensuu, 2012, Acta oncologica.

Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy

K. Aittomäki, J. Painter, A. Lehesjoki, 2005, European Journal of Human Genetics.

Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma.

B. Neyns, A. Michotte, N. Nupponen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Biology of Progression of Prostate Cancer

T. Visakorpi, N. Nupponen, 1999, European Urology.

Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis

J. Kononen, K. Syrjäkoski, H. Haapasalo, 1999, The Journal of pathology.

Mutation and copy number analysis of LNX1 and Numbl in nervous system tumors.

M. Tanner, N. Nupponen, A. Roselli, 2008, Cancer genetics and cytogenetics.

Prognostic significance of esterase gene expression in multiple myeloma

C. Heckman, N. Nupponen, M. M. Majumder, 2020, British Journal of Cancer.

Prostate Cancer Susceptibility Genes: Many Studies, Many Results, No Answers

J. Carpten, N. Nupponen, 2004, Cancer and Metastasis Reviews.

Molecular cytogenetics of prostate cancer

T. Visakorpi, N. Nupponen, Nina N. Nupponen, 2000, Microscopy research and technique.

Identification of novel transcription factor-like gene from human intestinal cells.

T. Visakorpi, M. Vihinen, M. Mäki, 2000, Biochemical and biophysical research communications.

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma

H. Joensuu, S. Nordling, H. Sihto, 2004, British Journal of Cancer.

Gene expression signatures for colorectal cancer microsatellite status and HNPCC

T. Ørntoft, L. Aaltonen, D. Arango, 2005, British Journal of Cancer.

MET Receptor Tyrosine Kinase Sequence Alterations in Differentiated Thyroid Carcinoma

K. Franssila, H. Joensuu, M. Karjalainen‐Lindsberg, 2005, The American journal of surgical pathology.

Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas

A. Paetau, J. Isola, H. Joensuu, 2006, Molecular Cancer Research.

KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

K. Franssila, H. Joensuu, M. Tanner, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma

P. Peltomäki, R. Butzow, N. Nupponen, 2007, International journal of cancer.

NF1-Associated Gastrointestinal Stromal Tumors Have Unique Clinical, Phenotypic, and Genotypic Characteristics

H. Joensuu, H. Sihto, L. Kindblom, 2005, The American journal of surgical pathology.

Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma

A. von Deimling, H. Joensuu, M. Nistér, 2011, International journal of cancer.

Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.

L. Aaltonen, S. Vanharanta, J. Isola, 2004, The American journal of pathology.

RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases

J. Witte, J. Carpten, J. Trent, 2002, Nature Genetics.

Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.

J. Carpten, J. Trent, S. Isaacs, 2001, American journal of human genetics.

5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines

C. Larsson, T. Visakorpi, J. Isola, 2001, Genes, chromosomes & cancer.

Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer.

T. Visakorpi, L. Bubendorf, T. Gasser, 2001, The American journal of pathology.

Mapping the amplification of EIF3S3 in breast and prostate cancer

T. Visakorpi, J. Isola, N. Nupponen, 2000, Genes, chromosomes & cancer.

Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.

K. Porkka, T. Visakorpi, Å. Borg, 1999, The American journal of pathology.

Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors

T. Visakorpi, H. Joensuu, M. Tanner, 2005, Journal of molecular medicine.

Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.

A. Poustka, T. Visakorpi, P. Peterson, 2005, Cancer research.

Little evidence for involvement of MLH3 in colorectal cancer predisposition

L. Aaltonen, P. Laiho, P. Peltomäki, 2003, International journal of cancer.

Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.

J. Isola, H. Joensuu, H. Sihto, 2006, Cancer genetics and cytogenetics.

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

Jorma Isola, Heikki Joensuu, J. Isola, 2006, Journal of Molecular Medicine.

Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping

C. Larsson, T. Visakorpi, J. Isola, 2000, Cytogenetic and Genome Research.

Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization.

T. Visakorpi, A. Kallioniemi, N. Nupponen, 1998, Cancer genetics and cytogenetics.

Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors

H. Haapasalo, O. Tynninen, M. Korja, 2010, Journal of Neuro-Oncology.

Stem cell protein BMI‐1 is an independent marker for poor prognosis in oligodendroglial tumours

A. Paetau, H. Haapasalo, O. Tynninen, 2008, Neuropathology and applied neurobiology.

Copy number alterations of the polycomb gene BMI1 in gliomas

M. Tanner, O. Tynninen, H. Sariola, 2008, Acta Neuropathologica.

Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17

O. Kallioniemi, A. Kallioniemi, M. Bärlund, 1998, Cytogenetic and Genome Research.

The tyrosine kinase c‐Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors

I. Leuschner, M. Frühwald, M. Hasselblatt, 2010, Cancer.

Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene.

M. Fernö, Å. Borg, J. Isola, 1998, The American journal of pathology.

No fumarate hydratase (FH) mutations in hereditary prostate cancer

D. Schaid, L. Aaltonen, J. Schleutker, 2003, Journal of medical genetics.

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

J. Blay, M. van Glabbeke, G. Demetri, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

L. Aaltonen, C. Morrison, S. Vanharanta, 2004, American journal of human genetics.

Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.

J. Carpten, J. Trent, J. Schleutker, 2002, American journal of human genetics.

Human pHyde is not a classical tumor suppressor gene in prostate cancer

T. Tammela, K. Porkka, R. Vessella, 2003, International journal of cancer.

Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic study

L. Peltonen, J. Rinne, K. Majamaa, 2004, The Lancet.

Amplification of hypoxia-inducible factor 1α gene in prostate cancer

Tapio Visakorpi, Ola Bratt, T. Visakorpi, 2001 .

Short communication Amplification of hypoxia-inducible factor 1 gene in prostate cancer

T. Visakorpi, N. Nupponen, O. Bratt, 2001 .

Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.

H. Joensuu, B. Nilsson, H. Sihto, 2006, Gastroenterology.

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen

Alexander Schepsky, A. Slipicevic, C. Heckman, 2021, Cancers.

Identification of a novel transcription factorlike gene repressed during TGF-B induced human intestinal epithelial cell differentiation

T. Visakorpi, M. Vihinen, M. Mäki, 2000 .

Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer.

T. Visakorpi, O. Saramäki, N. Nupponen, 2001, Cancer genetics and cytogenetics.

Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours

K. Franssila, J. Isola, H. Joensuu, 2006, Scandinavian journal of gastroenterology.

Erratum: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Concensus Conference of 20-21 March 2004, under the auspices of ESMO (Annals of Oncology (2005) vol. 16 (566-578))

J. Blay, G. Demetri, M. Glabbeke, 2005 .

Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.

M. Ringnér, P. Meltzer, J. Carpten, 2001, Cancer research.

Mutations in two short noncoding mononucleotide repeats in most microsatellite-unstable colorectal cancers.

Rainer Lehtonen, Bert Vogelstein, Jukka-Pekka Mecklin, 2005, Cancer research.

Abstract 1843: Melflufen efficacy in multiple myeloma withTP53aberrations

P. Richardson, A. Slipicevic, C. Heckman, 2020 .

Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas

M. Tanner, M. Hasselblatt, A. Jeibmann, 2008, Modern Pathology.

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death

A. Slipicevic, S. Holstein, C. Heckman, 2022, HemaSphere.

KIT overexpression induces proliferation in astrocytes in an imatinib‐responsive manner and associates with proliferation index in gliomas

P. Kovanen, O. Jänne, K. Peltonen, 2008, International journal of cancer.

Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer

J. Carpten, T. Tammela, R. Vessella, 2004, Genes, chromosomes & cancer.